Oncological combination therapy and its method of use
A combination of prinabulin and a CDK inhibitor like abemaciclib addresses the limitations of CDK inhibitor therapy by enhancing treatment efficacy in breast cancer, particularly in cases of resistance, through a co-administration approach.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- BEYONDSPRING PHARMACEUTICALS INC
- Filing Date
- 2024-05-20
- Publication Date
- 2026-06-16
AI Technical Summary
Despite the success of CDK inhibitor therapy for metastatic hormone receptor-positive breast cancer, only 60-70% of breast cancers respond to this treatment, and many patients develop resistance over time, necessitating improved anticancer therapies.
A combination therapy involving the co-administration of prinabulin and a cyclin-dependent kinase (CDK) inhibitor, such as abemaciclib, is administered to patients, with prinabulin given intravenously and abemaciclib orally, in varying doses and frequencies to enhance treatment efficacy.
The combination therapy effectively inhibits tumor growth in breast cancer models, offering a potential solution to overcome resistance and improve treatment outcomes for patients who do not initially respond or develop resistance to CDK inhibitor monotherapy.
Smart Images
Figure 2026519591000001_ABST